by Joshua Krieger, Danielle Li, and Dimitris Papanikolaou - Publications - Faculty & Research

09 Feb 2018
Working Paper Summaries

Developing Novel Drugs

Keywords: by Joshua Krieger, Danielle Li, and Dimitris Papanikolaou; Pharmaceutical

12 Jun 2018
Research & Ideas

In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?

their cash reserves have suddenly expanded—they tend to put that extra budget towards more exploratory projects,” says Harvard Business School Assistant Professor Joshua Krieger. He co-authored the study Developing Novel Drugs with View Details

Keywords: by Rachel Layne; Health; Pharmaceutical

2023
Working Paper

Evaluation and Learning in R&D Investment

By: Alexander P. Frankel, Joshua L. Krieger, Danielle Li and Dimitris Papanikolaou

We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach... View Details

Keywords: Research and Development; Forecasting and Prediction; Valuation; Pharmaceutical Industry

Citation

Read Now

Purchase

16 Jan 2018
First Look

First Look at New Research and Ideas, January 16, 2018

https://www.hbs.edu/faculty/Pages/item.aspx?num=53705 Developing Novel Drugs By: Krieger, Joshua, Danielle Li, and View Details

Keywords: Sean Silverthorne

2022
Article

Missing Novelty in Drug Development

By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou

We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to... View Details

Keywords: Drug Development; Risk Aversion; Research and Development; Innovation and Invention; Investment; Pharmaceutical Industry